darlifarnib Updated Jul 14
Investors should watch the KCRS 2026 oral presentation on July 24 and the virtual investor call on July 27 for updated long-term Phase 1a durability data in ccRCC. The program is too early for binary positioning, the real value inflection points (Phase 1b randomization data, Phase 3 start in 2028, and the daraxonrasib combo entering the clinic in early 2027) are 12+ months away. KURA is a multi-asset company with an approved product, so darlifarnib is one of several value drivers.
- Early Phase 1a data show compelling efficacy: darlifarnib + adagrasib achieved 67% confirmed ORR in pancreatic cancer (historically hard-to-treat), 50% in NSCLC, and 29% in KRASi-naïve CRC, with tumor shrinkage in 77% of evaluable patients (source: ASCO 2026 presentation via BioSpace press release).
- The FTI mechanism targets mTORC1-mediated resistance, a well-validated pathway; preclinical data from Cancer Research (May 2026) showed darlifarnib added to RAS inhibitors led to rapid and durable tumor regression in resistant models (source: AACR journal publication).
- Kura has a strong balance sheet ($667.2M cash as of Q4 2025 + ~$180M in anticipated collaboration payments) funding operations into Q4 2027, providing years of runway to develop darlifarnib without near-term dilution risk (source: Kura Q4 2025 earnings press release, GlobeNewswire).
- Darlifarnib is still only in Phase 1, no randomized controlled data, no Phase 2/3 results. The impressive 67% ORR in pancreatic cancer comes from small patient numbers (single digits) in an early dose-escalation cohort, not a registrational trial (source: ASCO 2026 abstract #3078).
- The registrational Phase 3 study is not planned until 2028, meaning FDA approval (if any) is 4-6+ years away. The next pivotal catalyst, Phase 1b randomized data, has no announced readout date, leaving a long data gap (source: Kura press releases).
- Short interest is elevated, the 14-day average short volume ratio was ~48% as of mid-July 2026, with a z-score of +1.84 on July 13 signaling elevated bearish positioning.